Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition

Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition

To correlate the variable clinical features of estrogen receptor positive (ER+) breast cancer with somatic alterations, we studied pre-treatment tumour biopsies accrued from patients in a study of neoadjuvant aromatase inhibitor (AI) therapy by massively parallel sequencing and analysis. Eighteen si...

Full description

Bibliographic Details
Main Authors: Ellis, Matthew J., Ding, Li, Shen, Dong, Luo, Jingqin, Suman, Vera J., Wallis, John W., Van Tine, Brian A., Hoog, Jeremy, Goiffon, Reece J., Goldstein, Theodore C., Ng, Sam, Lin, Li, Crowder, Robert, Snider, Jacqueline, Ballman, Karla, Weber, Jason, Chen, Ken, Koboldt, Daniel C., Kandoth, Cyriac, Schierding, William S., McMichael, Joshua F., Miller, Christopher A., Lu, Charles, Harris, Christopher C., McLellan, Michael D., Wendl, Michael C., DeSchryver, Katherine, Allred, D. Craig, Esserman, Laura, Unzeitig, Gary, Margenthaler, Julie, Babiera, G.V., Marcom, P. Kelly, Guenther, J.M., Leitch, Marilyn, Hunt, Kelly, Olson, John, Tao, Yu, Maher, Christopher A., Fulton, Lucinda L., Fulton, Robert S., Harrison, Michelle, Oberkfell, Ben, Du, Feiyu, Demeter, Ryan, Vickery, Tammi L., Elhammali, Adnan, Piwnica-Worms, Helen, McDonald, Sandra, Watson, Mark, Dooling, David J., Ota, David, Chang, Li-Wei, Bose, Ron, Ley, Timothy J., Piwnica-Worms, David, Stuart, Joshua M., Wilson, Richard K., Mardis, Elaine R.
Format: Online
Language:English
Published: 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383766/
Description
Summary:To correlate the variable clinical features of estrogen receptor positive (ER+) breast cancer with somatic alterations, we studied pre-treatment tumour biopsies accrued from patients in a study of neoadjuvant aromatase inhibitor (AI) therapy by massively parallel sequencing and analysis. Eighteen significantly mutated genes were identified, including five genes (RUNX1, CBFB, MYH9, MLL3 and SF3B1) previously linked to hematopoietic disorders. Mutant MAP3K1 was associated with Luminal A status, low grade histology and low proliferation rates whereas mutant TP53 associated with the opposite pattern. Moreover, mutant GATA3 correlated with suppression of proliferation upon AI treatment. Pathway analysis demonstrated mutations in MAP2K4, a MAP3K1 substrate, produced similar perturbations as MAP3K1 loss. Distinct phenotypes in ER+ breast cancer are associated with specific patterns of somatic mutations that map into cellular pathways linked to tumor biology but most recurrent mutations are relatively infrequent. Prospective clinical trials based on these findings will require comprehensive genome sequencing.

Similar Items